• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)

    7/22/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email

    Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro:

    • Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.i
    • Kills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.ii
    • Achieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,ii
    • Outlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,ii

    INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterinarians and pet owners want it done fast. New data published in Parasites & Vectors, a leading peer-reviewed publication, demonstrates that Elanco Animal Health's (NYSE:ELAN) Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) kills ticks1 faster2 than leading competitors Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets).i

    Newly Published Data Found Credelio Quattro:

    • Faster2 Tick1 Speed of Kill: Credelio Quattro is the only product proven to significantly reduce black-legged ticks within 8 hours.i  Lotilaner, the active ingredient in Credelio Quattro also has the fastest initial tick speed of kill against the lone star tick - in just 12 hours – and sustains the advantage throughout the dosing interval.ii
    • Outperforms the Competition: Outperforms Simparica Trio® (12 hours) and NexGard® Plus (24 hours) at the end of the dosing period (Day 28).i
    • Consistency Over Competitors: Achieves 8-hour speed of kill1 on Day 0 and on Day 28 with no performance drop-off. Rapid kill is critical for preventing Lyme disease transmission, which typically occurs 24-48 hours after attachment.i

    "Speed of kill is a critical factor for veterinarians and pet owners when choosing parasite coverage because the longer a tick is attached, the more likely it is to transmit dangerous diseases, like Lyme disease, to pets," said Dr. Casey Locklear, veterinarian and leading parasiticides expert at Elanco. "These results reinforce that lotilaner, the active ingredient in Credelio Quattro, not only starts working fast but maintains its speed of kill4 against multiple species of ticks5, providing veterinarians and pet owners with the confidence that their dogs are protected from the very start of the month to the very end."

    The black-legged tick is the primary vector for Borrelia burgdorferi, the bacterium responsible for Lyme disease and anaplasmosis. The study, which evaluated the speed of kill against Ixodes scapularis (black-legged tick), found that Credelio Quattro was the only product tested to achieve significant initial tick reduction2 within just 8 hours of infestation. Notably, this rapid speed of kill1 was maintained from the beginning of the month through Day 28, providing consistent protection for the entire dosing interval.i

    "Ticks are on the move. They are no longer limited to the places or seasons where we have historically expected to find them," said Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. "As their geographic range expands, so does the risk of tick bites and exposure to the pathogens they carry. Because tick-borne diseases can threaten the health of people, pets, and livestock, raising public awareness is more important than ever as tick populations grow and spread into new regions."

    The findings are based on evaluation time points at 4, 8, 12, 24, and 48 hours post-treatment and reinfestation. The data demonstrates that Credelio Quattro outperforms Simparica Trio and NexGard Plus in rapid tick1 reduction, particularly in the critical first 8 to 12 hours.i

    Speed of kill against Ixodes scapularis (black-legged tick)^ i

    Time point at which active achieved consistent superior efficacy vs. untreated control group¥ 

    Day of Study 

    Credelio Quattro

    (lotilaner, moxidectin, praziquantel, and pyrantel)

    Simparica Trio

    (sarolaner, moxidectin and pyrantel)

    NexGard Plus

    (afoxolaner, moxidectin, and pyrantel)

    0

    8 hrs 

    12 hrs 

    12 hrs 

    21

    8 hrs 

    24 hrs 

    24 hrs 

    28

    8 hrs 

    12 hrs 

    24 hrs 

    ^Tick counts were evaluated at all 4-, 8-, 12-, 24-, and 48-hour time points as part of the study design 

    ¥P<0.05. 

    Credelio Quattro also has a U.S. Food and Drug Administration approved claim for prevention of Lyme disease in dogs as a direct result of killing black-legged ticks.

    Does Credelio Quattro Kill the Lone Star Tick?

    Credelio Quattro is approved to protect dogs from the lone star tick (Amblyomma americanum), and its active ingredient, lotilaner, also has the fastest3 initial speed of tick kill against the lone star tick – in just 12 hours – and sustains that advantage throughout the dosing interval.ii This aggressive and expanding tick species – established across the South, Midwest and Northeast, and continuing to spread –  is one of the hardest to kill and is best known for its association with alpha-gal syndrome, or the red meat allergy in humans. It can also transmit dangerous disease-causing pathogens to dogs.iii A 2024 head-to-head study published in Parasites & Vectors compared lotilaner, the active ingredient in Credelio (lotilaner) and Credelio Quattro with sarolaner in Simparica Trio and afoxolaner in NexGard®, and found that lotilaner kills the lone star tick faster4 than sarolaner in Simparica Trio and afoxolaner in NexGard, protecting dogs against this pathogen-carrying tick.  

    Speed of kill against Amblyomma americanum (lone star tick)^ ii

    Time point at which active achieved consistent superior efficacy vs. untreated control group¥ 

    Day of Study

    Credelio

    (lotilaner)

    Sarolaner

    (sarolaner, moxidectin and pyrantel)

    NexGard

    (afoxolaner)

    0

    12 hrs

    24 hrs

    24 hrs

    21

    12 hrs

    48 hrs

    48 hrs

    28

    8 hrs

    48 hrs

    72 hrs

    ^Tick counts were evaluated at all 4-, 8-, 12-, 24-, 48-, and 72-hour time points as part of the study design 

    ¥P<0.05. 

    "With a heavier tick season and emergency room visits from tick bites on the riseiv, pet owners should remain vigilant and keep their pets on year-round parasite coverage," Dr. Locklear notes. "We continue to look for opportunities to make parasite protection stronger and evolve research around best-in-class medicines."

    Frequently Asked Questions About Ticks and Credelio Quattro:

    How fast does Credelio Quattro kill ticks? 

    Studies show that lotilaner, the active ingredient in Credelio Quattro kills ticks5  faster6 than the competition.i,ii A 2026 study published in Parasites & Vectors shows that Credelio Quattro achieved significant reduction2 of black-legged ticks within 8 hours of infestation.i A 2024 study shows that lotilaner, the active ingredient in Credelio and Credelio Quattro also has the fastest3 initial speed of tick kill against the lone star tick – in just 12 hours – and sustains that advantage throughout the dosing interval.ii

    Why is it important to kill ticks quickly?

    The risk of disease transmission increases the longer a tick remains attached, making rapid speed of kill a critical factor in preventing the transmission of disease. A 2026 study shows that Credelio Quattro was the only product tested that significantly reduced2 black-legged ticks within 8 hours.i

    Does Credelio Quattro lose effectiveness to kill ticks1 quickly at the end of the month? 

    No. The data shows that Credelio Quattro maintains its 8-hour speed of kill2 on Day 28, whereas competitors showed a decline in performance.i

    Are black-legged ticks linked to the red meat allergy in humans?

    In the United States, alpha-gal syndrome, or red meat allergy, is usually associated with bites from the lone star tick (Amblyomma americanum); however, two Emerging Infectious Diseases studies link bites from black-legged ticks (deer ticks) and western black-legged ticks to potentially life-threatening alpha-gal syndrome.v Additional work will be needed to determine a possible link, according to the researchers, but this continues to put emphasis on the need for tick bite protection for humans.

    To learn more about Credelio Quattro visit CredelioQuattroVet.com.

    PM-US-26-1188

    1. Ixodes scapularis (black-legged tick)
    2. Based on the time to statistical significance vs. control in a head-to-head study on Day 0 post-treatment and Day 28 for reinfestations comparing Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against Ixodes scapularis.
    3. Based on the time to statistical significance vs. control in a head-to-head study comparing Credelio (lotilaner)—not Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard (afoxolaner). 
    4. Based on the time to statistical significance vs control in two separate head-to-head studies. The first study compared Credelio (lotilaner)—not Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard (afoxolaner) against Amblyomma americanum. The second study compared Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against I. scapularis.
    5. Ixodes scapularis (black-legged tick) and Amblyomma americanum (lone star tick)

    NexGard and NexGard Plus are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. Simparica Trio is a registered trademark of Zoetis Services LLC.

    Credelio Quattro, Credelio, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Other company and product names are trademarks of their respective owners. © 2026 Elanco or its affiliates

    ABOUT ELANCO

    Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

    Indications for Credelio Quattro/Credelio Quattro-CA1

    Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

    Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.

    Important Safety Information for Credelio Quattro/Credelio Quattro-CA1

    Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

    Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.

    For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.

    Indications for Credelio

    Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

    Important Safety Information for Credelio

    Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.

    i Reif, K.E., Kollasch, T.M., Locklear, C.L. et al. Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio™), afoxolaner (NexGard® PLUS), or lotilaner (Credelio Quattro™). Parasites Vectors (2026). https://doi.org/10.1186/s13071-026-07559-y

    ii
      Reif KE, Kollasch TM, Neilson JC, Herrin BH, Ryan WG, Bell MC, Beltz MS, Dryden MW, Jesudoss Chelladurai JRJ, Miller KR, Sutherland CJ. Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs. Parasite Vectors. 2024 Jul 20;17(1):313.

    iii Centers for Disease Control and Prevention. (n.d.). Where Ticks Live. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from https://www.cdc.gov/ticks/about/where-ticks-live.html

    iv CDC Data Show Weekly ER Visits for Tick Bites Higher Than Usual." Centers for Disease Control and Prevention, 23 Apr. 2026,

    v Van Beusekom, Mary. "Research Ties Bites from 2 More Types of Ticks to Red Meat Allergy." CIDRAP (Center for Infectious Disease Research and Policy), 4 Apr. 2025

    Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com

    Media Contact: Season Solorio (765) 316-0233 season.solorio@elancoah.com

    Elanco logo

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/credelio-quattro-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tablets-kills-ticks-faster-than-simparica-trio-sarolaner-moxidectin-and-pyrantel-chewable-tablets-and-nexgard-plus-afoxolaner-moxidectin-and-302831444.html

    SOURCE Elanco Animal Health

    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    4/15/2026$30.00Buy
    Citigroup
    1/22/2026Neutral → Overweight
    Piper Sandler
    12/9/2025$30.00Overweight
    Barclays
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    11/19/2025$25.00Hold → Buy
    Argus
    10/7/2025$24.00Neutral → Overweight
    Analyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)

    Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro:Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.iKills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.iiAchieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,iiOutlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,iiINDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterin

    7/22/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/news-events/events-presentation. A replay will also be available on the website shor

    7/8/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health

    New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutionsINDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced plans to establish Elanco Ventures, a dedicated corporate venture capital (CVC) platform designed to support, invest and advance innovation in animal health. To be backed by a $25 million multi-year commitment, Elanco Ventures will initially focus on strategic investments in therapeutic advancements and supportive technologies across the animal health sector."From pets to protein – the animal health industry has

    6/18/26 7:26:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Modi Rajeev A. bought $99,939 worth of shares (4,911 units at $20.35), increasing direct ownership by 3% to 160,812 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:39:20 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $99,843 worth of shares (4,971 units at $20.09) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:38:26 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/14/26 4:15:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/14/26 4:15:12 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/14/26 4:14:31 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Elanco Animal Health Incorporated

    SCHEDULE 13G - Elanco Animal Health Inc (0001739104) (Subject)

    7/14/26 1:27:07 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by Elanco Animal Health Incorporated

    SD - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:09:19 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:00:57 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer

    National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC

    4/24/26 9:00:00 AM ET
    $ACHC
    $ELAN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Elanco Animal Health with a new price target

    Citigroup initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $30.00

    4/15/26 8:08:24 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/news-events/events-presentation. A replay will also be available on the website shor

    7/8/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports First Quarter 2026 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y

    5/6/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.asp

    4/16/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care